All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


← First12345...718Next →

hiv & aids news selected from other sources

  • Tuberculosis and HIV
    TB/HIV Research Frontiers Meeting in conjunction with the 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015)
    World Health Organization | 1 hour ago

    The objective of the meeting was to discuss and promote high level scientific interchange on ideas and updates about ongoing clinical trials on empirical TB treatment for preventing early mortality in people living with HIV and assess their eventual impact on policy change. The meeting also discussed the prospect of using rifamycins for prevention of tuberculosis in resource limited settings with high TB and HIV prevalence.

  • Treatment interruptions
    Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients
    The Body | 1 hour ago

    Biomarkers of immune exhaustion were associated with how long a patient was able to control HIV after treatment was interrupted, according to a study presented at CROI 2015.

  • Hepatitis C treatment
    Natco Pharma ties up with Gilead on hepatitis C drugs
    Reuters | 17 hours ago

    Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

  • Hepatitis C treatment
    HCV Drugs Costly but Cure Might Not Be
    MedPage Today | 17 hours ago

    Despite controversy over the cost of new hepatitis C (HCV) medications, they appear to be cheaper on a per-cure basis than earlier drugs, a researcher said here.

  • Bad science and bogus treatments
    Pakistan: Factory making fake Hepatitis C drug raided
    The International News | 17 hours ago

    Assisted by the Federal Investigation Authority (FIA), personnel of the Drug Regulatory Authority of Pakistan (DRAP) raided one of the local industries in Islamabad’s Kahuta industrial area here Saturday, leading to the discovery of unlawful manufacturing of Sofasbuvir tablets, which are used for the treatment of Hepatitis C, and Everlong tablets, the registration of which has long been withdrawn.

  • Discrimination and the law
    Emirati man with HIV held for more than a decade at health facility
    The National | 20 hours ago

    An Emirati man with HIV has been waiting 16 years to be released from a government clinic because his family won’t give their consent. The centre stipulates that a family member must consent to Mr Al Mazrouei’s release.

  • Task shifting
    Health workforce shortage weakens AIDS response
    Science Speaks | 23 hours ago

    While the U.S. government has helped train more than 140,000 healthcare workers through the U.S. President’s Emergency Plan for AIDS Relief since the program was re-authorized in 2008, Africa still needs more than one million healthcare workers to address a critical shortage, U.S. Global AIDS Ambassador Dr. Deborah Birx said Monday at a Capitol Hill briefing.

  • The search for a cure
    Study of potential HIV 'cure' wins FDA nod
    San Francisco Business Times | 23 hours ago

    The trial at the City of Hope medical center will take blood-producing stem cells from patients infected with HIV and use a kind of molecular scissors — enzymes called zinc finger nucleases — to edit a protein that the virus uses to infect cells. The method was developed by Richmond's Sangamo BioSciences Inc.

  • Lipodystrophy
    Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start
    BETA blog | 23 hours ago

    New findings show that people with higher viral loads when starting ART for the first time are more likely to undergo substantial body composition changes, such as an increased amount of fat in the abdominal area (called “central adiposity”), than those who start treatment with a lower viral load (abstract 140).

  • Starting treatment
    Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3
    HIV i-Base | 03 March 2015

    The TEMPRANO study presented as a late breaker oral presentation, included important information for timing of TB prophylaxis and the timing of ART in TB-endemic countries. The conclusions though do not support universally starting treatment at CD4 counts >500 or answer the primary question of the international START study.

← First12345...1017Next →

Hepatitis C news

WHO recommends global use of newest hepatitis C drugs, urges price reductions.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Treatment as prevention

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in two years of PARTNER study.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.